$KNSA
Kiniksa Pharmaceuticals Ltd

2022 Q4 Form 10-K Financial Statement

#000155837023002684 Filed on March 02, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022
Revenue $61.88M $220.2M
YoY Change 230.14% 471.24%
Cost Of Revenue $6.710M $22.90M
YoY Change 73.52% 151.59%
Gross Profit $55.17M $197.3M
YoY Change 270.84% 570.03%
Gross Profit Margin 89.16% 89.6%
Selling, General & Admin $27.22M $97.95M
YoY Change 19.67% 13.97%
% of Gross Profit 49.33% 49.65%
Research & Development $14.39M $65.49M
YoY Change -47.54% -34.05%
% of Gross Profit 26.08% 33.2%
Depreciation & Amortization $602.0K $1.179M
YoY Change -9.88% -18.97%
% of Gross Profit 1.09% 0.6%
Operating Expenses $49.13M $163.4M
YoY Change -3.69% -11.77%
Operating Profit $6.047M $9.773M
YoY Change -116.74% -106.24%
Interest Expense $794.0K $1.253M
YoY Change 931.17% 1191.75%
% of Operating Profit 13.13% 12.82%
Other Income/Expense, Net
YoY Change
Pretax Income $6.841M $11.03M
YoY Change -118.97% -107.04%
Income Tax $2.380M -$172.3M
% Of Pretax Income 34.79% -1563.01%
Net Earnings $4.461M $183.4M
YoY Change -112.28% -216.11%
Net Earnings / Revenue 7.21% 83.28%
Basic Earnings Per Share $2.64
Diluted Earnings Per Share $0.06 $2.60
COMMON SHARES
Basic Shares Outstanding 69.38M
Diluted Shares Outstanding 70.42M

Balance Sheet

Concept 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $190.6M $190.6M
YoY Change 4.61% 4.61%
Cash & Equivalents $122.7M $122.7M
Short-Term Investments $67.89M $67.89M
Other Short-Term Assets $10.54M $10.54M
YoY Change 60.02% 60.02%
Inventory $21.60M $21.60M
Prepaid Expenses
Receivables $12.66M $20.32M
Other Receivables $0.00 $0.00
Total Short-Term Assets $243.1M $243.1M
YoY Change 23.73% 23.73%
LONG-TERM ASSETS
Property, Plant & Equipment $1.658M $7.043M
YoY Change -41.5% -15.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.824M $191.3M
YoY Change -33.21% 2094.03%
Total Long-Term Assets $216.6M $216.6M
YoY Change 495.84% 495.84%
TOTAL ASSETS
Total Short-Term Assets $243.1M $243.1M
Total Long-Term Assets $216.6M $216.6M
Total Assets $459.7M $459.7M
YoY Change 97.45% 97.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.899M $7.899M
YoY Change 322.86% 322.86%
Accrued Expenses $30.11M $33.41M
YoY Change -20.82% -19.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $47.07M $47.07M
YoY Change 5.0% 5.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.839M $16.46M
YoY Change 581.11% 459.95%
Total Long-Term Liabilities $1.839M $16.46M
YoY Change 581.11% 459.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $47.07M $47.07M
Total Long-Term Liabilities $1.839M $16.46M
Total Liabilities $63.52M $63.52M
YoY Change 33.0% 33.0%
SHAREHOLDERS EQUITY
Retained Earnings -$492.0M
YoY Change -27.15%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $396.1M $396.1M
YoY Change
Total Liabilities & Shareholders Equity $459.7M $459.7M
YoY Change 97.45% 97.45%

Cashflow Statement

Concept 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $4.461M $183.4M
YoY Change -112.28% -216.11%
Depreciation, Depletion And Amortization $602.0K $1.179M
YoY Change -9.88% -18.97%
Cash From Operating Activities -$11.58M $5.807M
YoY Change -38.7% -104.6%
INVESTING ACTIVITIES
Capital Expenditures -$32.00K $105.0K
YoY Change -87.25% -74.7%
Acquisitions
YoY Change
Other Investing Activities -$42.69M -$7.973M
YoY Change -14.26% -105.35%
Cash From Investing Activities -$42.66M -$8.078M
YoY Change -14.75% -106.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.190M 2.516M
YoY Change -1.82% -57.25%
NET CHANGE
Cash From Operating Activities -11.58M 5.807M
Cash From Investing Activities -42.66M -8.078M
Cash From Financing Activities 1.190M 2.516M
Net Change In Cash -53.05M 245.0K
YoY Change -21.66% -97.02%
FREE CASH FLOW
Cash From Operating Activities -$11.58M $5.807M
Capital Expenditures -$32.00K $105.0K
Free Cash Flow -$11.54M $5.702M
YoY Change -38.05% -104.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3985000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7656000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1658000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2834000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5385000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5550000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5824000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8720000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2669000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1839000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
270000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-67000
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001730430
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 knsa Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q4 knsa Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-38492
CY2022 dei Entity Registrant Name
EntityRegistrantName
Kiniksa Pharmaceuticals, Ltd.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
D0
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1327726
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
Clarendon House
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
2 Church Street
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Hamilton
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
HM11
CY2022 dei Entity Address Country
EntityAddressCountry
BM
CY2022 dei City Area Code
CityAreaCode
808
CY2022 dei Local Phone Number
LocalPhoneNumber
189-6257
CY2022 dei Security12b Title
Security12bTitle
Class A Common Shares
CY2022 dei Trading Symbol
TradingSymbol
KNSA
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
346700000
CY2022 dei Auditor Firm
AuditorFirmId
238
CY2022 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2022Q4 us-gaap Inventory Net
InventoryNet
21599000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3675000
CY2022 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122715000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122470000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
67893000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
59731000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10537000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6585000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12660000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
243060000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
196446000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18250000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19250000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
185495000
CY2022Q4 us-gaap Assets
Assets
459672000
CY2021Q4 us-gaap Assets
Assets
232800000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7899000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1868000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30112000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38031000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3301000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3381000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5754000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1544000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
47066000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44824000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12000000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2618000
CY2022Q4 us-gaap Liabilities
Liabilities
63523000
CY2021Q4 us-gaap Liabilities
Liabilities
47763000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
888120000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-157924000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-161381000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
110000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-32000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-67000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
860482000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
44000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-66000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-492034000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-675397000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
396149000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185037000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
459672000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
232800000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
220180000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38544000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65490000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
99297000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
112042000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
97951000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
85948000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
45321000
CY2022 knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
210407000
CY2021 knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
195180000
CY2020 knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
157363000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
9773000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-156636000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-157363000
CY2022 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1253000
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
97000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1134000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11026000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-156539000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-156229000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-172337000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1385000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5152000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
183363000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-157924000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-161381000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.64
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.30
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.61
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.60
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.30
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.61
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69382275
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68576810
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61842722
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70421322
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68576810
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61842722
CY2022 us-gaap Net Income Loss
NetIncomeLoss
183363000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
110000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-32000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
183473000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-157956000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-161448000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
225423000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
6552000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20875000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-67000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-161381000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
311935000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
5885000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25173000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-32000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-157924000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185037000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
2519000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25120000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
396149000
CY2022 us-gaap Profit Loss
ProfitLoss
183363000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
110000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
183363000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
415000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
283000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
135864000
CY2021 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
157250000
CY2021 us-gaap Profit Loss
ProfitLoss
-157924000
CY2020 us-gaap Profit Loss
ProfitLoss
-161381000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2402000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2355000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2405000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
25120000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
25173000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
20875000
CY2022 knsa Noncash Lease Expense
NoncashLeaseExpense
3041000
CY2021 knsa Noncash Lease Expense
NoncashLeaseExpense
2631000
CY2020 knsa Noncash Lease Expense
NoncashLeaseExpense
1400000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
82000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-664000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-123000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-33000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-103000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-185495000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
11000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
4361000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3858000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2941000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1334000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8675000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3910000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
17924000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3675000
CY2022 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
7656000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2654000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3284000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5588000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6031000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1366000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4969000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3709000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10339000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8797000
CY2022 knsa Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3007000
CY2021 knsa Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2553000
CY2020 knsa Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1699000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
12000000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1569000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-535000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
478000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5807000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-126298000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-136532000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
91000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
105000
CY2020 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
430211000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
127800000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
306300000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
407050000
CY2020 us-gaap Depreciation
Depreciation
2405000
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
20000000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8078000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
128635000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23444000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1136000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
3417000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
5885000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
6553000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
901000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2516000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5885000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
227086000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
245000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8222000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
67110000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122470000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114248000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47138000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122715000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122470000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114248000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
10689000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1279000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
482000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2876000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1619000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6039000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue, the accrual for research and development expenses, the valuation of our deferred tax assets and the valuation of share-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p>
CY2021Q4 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
210000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-492034000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
183363000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5807000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
190608000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. As of December 31, 2022 and 2021, substantially all of the Company’s cash, cash equivalents and short-term investments were held at two financial institutions. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash, cash equivalents and short-term investments and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from the accounts receivable related to product revenue. The majority of trade accounts receivable are recorded net of allowances for cash discounts associated with prompt payments from customers. All trade accounts receivable arise from product revenue in the United States due from the Company’s third party logistics provider. There were no material write-offs charged against the allowance for the year ended December 31, 2022.</p>
CY2021 knsa Concentration Risk Number Of Financial Institutions
ConcentrationRiskNumberOfFinancialInstitutions
2
CY2022 knsa Concentration Risk Number Of Financial Institutions
ConcentrationRiskNumberOfFinancialInstitutions
2
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20000000
CY2021Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P20Y
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2021Q4 knsa Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q4 knsa Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022 knsa Number Of Securities Unrealized Loss Position
NumberOfSecuritiesUnrealizedLossPosition
2
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
7471000
CY2021 knsa Number Of Securities Unrealized Loss Position
NumberOfSecuritiesUnrealizedLossPosition
11
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
49739000
CY2021Q4 knsa Product Revenue Reserve For Contractual Adjustments
ProductRevenueReserveForContractualAdjustments
515000
CY2021Q4 knsa Product Revenue Reserve For Government Rebates
ProductRevenueReserveForGovernmentRebates
719000
CY2021Q4 knsa Product Revenue Reserve For Sales Returns
ProductRevenueReserveForSalesReturns
101000
CY2021Q4 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
1335000
CY2022 knsa Product Revenue Provision For Contractual Adjustments
ProductRevenueProvisionForContractualAdjustments
7366000
CY2022 knsa Product Revenue Provision For Government Rebates
ProductRevenueProvisionForGovernmentRebates
4543000
CY2022 knsa Product Revenue Provision For Product Returns
ProductRevenueProvisionForProductReturns
269000
CY2022 knsa Product Revenue Provision For Reserves And Allowances
ProductRevenueProvisionForReservesAndAllowances
12178000
CY2022 knsa Product Revenue Returns Adjustments Prior Year Sales
ProductRevenueReturnsAdjustmentsPriorYearSales
19000
CY2022 knsa Product Revenue Adjustments For Reserves And Allowances Prior Year Sales
ProductRevenueAdjustmentsForReservesAndAllowancesPriorYearSales
19000
CY2022 knsa Product Revenue Refunds On Contractual Adjustments
ProductRevenueRefundsOnContractualAdjustments
5902000
CY2022 knsa Product Revenue Refunds And Payments On Government Rebates
ProductRevenueRefundsAndPaymentsOnGovernmentRebates
2535000
CY2022 knsa Product Revenue Refunds And Credits For Reserves And Allowances
ProductRevenueRefundsAndCreditsForReservesAndAllowances
8437000
CY2022 knsa Product Revenue Contractual Adjustments Payments And Sales Returns Prior Year Sales
ProductRevenueContractualAdjustmentsPaymentsAndSalesReturnsPriorYearSales
515000
CY2022 knsa Product Revenue Government Rebates Payments And Sales Returns Prior Year Sales
ProductRevenueGovernmentRebatesPaymentsAndSalesReturnsPriorYearSales
643000
CY2022 knsa Product Revenue Refunds And Credits For Reserves And Allowances Prior Year Sales
ProductRevenueRefundsAndCreditsForReservesAndAllowancesPriorYearSales
1158000
CY2022Q4 knsa Product Revenue Reserve For Contractual Adjustments
ProductRevenueReserveForContractualAdjustments
1464000
CY2022Q4 knsa Product Revenue Reserve For Government Rebates
ProductRevenueReserveForGovernmentRebates
2084000
CY2022Q4 knsa Product Revenue Reserve For Sales Returns
ProductRevenueReserveForSalesReturns
351000
CY2022Q4 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
3899000
CY2021 knsa Product Revenue Provision For Contractual Adjustments
ProductRevenueProvisionForContractualAdjustments
2219000
CY2021 knsa Product Revenue Provision For Government Rebates
ProductRevenueProvisionForGovernmentRebates
1131000
CY2021 knsa Product Revenue Provision For Product Returns
ProductRevenueProvisionForProductReturns
327000
CY2021 knsa Product Revenue Provision For Reserves And Allowances
ProductRevenueProvisionForReservesAndAllowances
3677000
CY2021 knsa Product Revenue Refunds On Contractual Adjustments
ProductRevenueRefundsOnContractualAdjustments
1704000
CY2021 knsa Product Revenue Refunds And Payments On Government Rebates
ProductRevenueRefundsAndPaymentsOnGovernmentRebates
412000
CY2021 knsa Product Revenue Refunds On Product Returns
ProductRevenueRefundsOnProductReturns
226000
CY2021 knsa Product Revenue Refunds And Credits For Reserves And Allowances
ProductRevenueRefundsAndCreditsForReservesAndAllowances
2342000
CY2021Q4 knsa Product Revenue Reserve For Contractual Adjustments
ProductRevenueReserveForContractualAdjustments
515000
CY2021Q4 knsa Product Revenue Reserve For Government Rebates
ProductRevenueReserveForGovernmentRebates
719000
CY2021Q4 knsa Product Revenue Reserve For Sales Returns
ProductRevenueReserveForSalesReturns
101000
CY2021Q4 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
1335000
CY2022 knsa Product Revenue Provision For Specific Product Returns
ProductRevenueProvisionForSpecificProductReturns
226000
CY2022Q4 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
3899000
CY2021Q4 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
1335000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6312000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
15287000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3675000
CY2022Q4 us-gaap Inventory Net
InventoryNet
21599000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3675000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8517000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8749000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6859000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5915000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1658000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2834000
CY2022 us-gaap Depreciation
Depreciation
1179000
CY2021 us-gaap Depreciation
Depreciation
1455000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
750000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
3380000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
2748000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
1578000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
132000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
287000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
167000
CY2022 us-gaap Lease Cost
LeaseCost
3512000
CY2021 us-gaap Lease Cost
LeaseCost
3035000
CY2020 us-gaap Lease Cost
LeaseCost
1745000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M17D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0556
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3519000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2671000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6190000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
271000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5919000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
20000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1750000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18250000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
20000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19250000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1000000
CY2022Q4 knsa Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
8378000
CY2021Q4 knsa Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
24977000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11213000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8916000
CY2022Q4 knsa Accrued Collaboration Expenses Current
AccruedCollaborationExpensesCurrent
7522000
CY2021Q4 knsa Accrued Collaboration Expenses Current
AccruedCollaborationExpensesCurrent
835000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2866000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2933000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
133000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
370000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30112000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38031000
CY2022 knsa Decrease In Accrued Research And Development Expenses
DecreaseInAccruedResearchAndDevelopmentExpenses
2223000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000273235
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000273235
CY2022 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2022 knsa Period Of Equal Monthly Vesting After First Anniversary Option With Six Year Vesting
PeriodOfEqualMonthlyVestingAfterFirstAnniversaryOptionWithSixYearVesting
P5Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9226846
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.14
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14947000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2929315
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.37
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
383106
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.80
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1628437
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.73
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10144618
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.36
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M29D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
32634000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5661613
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.61
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M8D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
20612000
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
10144618
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
13.36
CY2022 knsa Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P7Y3M29D
CY2022Q4 knsa Share Based Compensation Arrangement By Share Based Payment Award Unvested Options Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedOptionsIntrinsicValue
32634000
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
383106
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2196000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2606000
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
795404
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6392000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5311000
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1324429
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
18271000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6058000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
885021
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
15.72
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1479861
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies State And Local
EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
0.104
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-156229000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.53
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
250805
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
14.81
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
371676
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
13.53
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1742401
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
12.76
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25120000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25173000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20875000
CY2022Q3 knsa Number Of Performance Obligations
NumberOfPerformanceObligations
4
CY2022Q1 knsa Time Period To Terminate Agreement If No Material Development Or Commercialization In China
TimePeriodToTerminateAgreementIfNoMaterialDevelopmentOrCommercializationInChina
P60D
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-84067000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-164284000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-161983000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
95093000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
7745000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
5754000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11026000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-156539000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1318000
CY2022 knsa Current Foreign Federal Tax Expense Benefit
CurrentForeignFederalTaxExpenseBenefit
4393000
CY2021 knsa Current Foreign Federal Tax Expense Benefit
CurrentForeignFederalTaxExpenseBenefit
682000
CY2020 knsa Current Foreign Federal Tax Expense Benefit
CurrentForeignFederalTaxExpenseBenefit
392000
CY2022 knsa Current Foreign State And Local Tax Expense Benefit
CurrentForeignStateAndLocalTaxExpenseBenefit
3117000
CY2021 knsa Current Foreign State And Local Tax Expense Benefit
CurrentForeignStateAndLocalTaxExpenseBenefit
706000
CY2020 knsa Current Foreign State And Local Tax Expense Benefit
CurrentForeignStateAndLocalTaxExpenseBenefit
366000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
4330000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-14000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
33000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
13158000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1374000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
791000
CY2020 knsa Deferred Foreign Federal Income Tax Expense Benefit
DeferredForeignFederalIncomeTaxExpenseBenefit
3056000
CY2020 knsa Deferred Foreign State And Local Income Tax Expense Benefit
DeferredForeignStateAndLocalIncomeTaxExpenseBenefit
1315000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-185495000
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
11000
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-10000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-185495000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
11000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
4361000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-172337000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1385000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5152000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
1.659
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.019
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.008
CY2022 knsa Effective Income Tax Rate Reconciliation Research And Development Tax Credits
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentTaxCredits
-0.215
CY2021 knsa Effective Income Tax Rate Reconciliation Research And Development Tax Credits
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentTaxCredits
0.024
CY2020 knsa Effective Income Tax Rate Reconciliation Research And Development Tax Credits
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentTaxCredits
0.024
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.132
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.013
CY2020 knsa Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies State And Local
EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
-0.005
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies State And Local
EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.359
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.014
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.006
CY2022 knsa Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
0.143
CY2021 knsa Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
0.002
CY2020 knsa Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
-0.002
CY2022 knsa Effective Income Tax Rate Reconciliation Ip Transfer Percent
EffectiveIncomeTaxRateReconciliationIpTransferPercent
-3.439
CY2021 knsa Effective Income Tax Rate Reconciliation Ip Transfer Percent
EffectiveIncomeTaxRateReconciliationIpTransferPercent
0.710
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.172
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.009
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-13.828
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.761
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.057
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-15.631
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.009
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.033
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
231000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1620000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
11789000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9492000
CY2022Q4 knsa Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1543000
CY2021Q4 knsa Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1574000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2134000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1869000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
181458000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
107037000
CY2022Q4 knsa Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
5586000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4054000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8559000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
206795000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
130151000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19584000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
127944000
CY2022Q4 knsa Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
312000
CY2021Q4 knsa Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
762000
CY2022Q4 knsa Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
1404000
CY2021Q4 knsa Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
1445000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
185495000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-185495000
CY2022 knsa Valuation Allowance Expiration
ValuationAllowanceExpiration
P1Y
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
127944000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9307000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
330000
CY2022 knsa Valuation Allowance Deferred Tax Asset Change In Amount Income Tax Provision
ValuationAllowanceDeferredTaxAssetChangeInAmountIncomeTaxProvision
-108360000
CY2021 knsa Valuation Allowance Deferred Tax Asset Change In Amount Income Tax Provision
ValuationAllowanceDeferredTaxAssetChangeInAmountIncomeTaxProvision
118637000
CY2020 knsa Valuation Allowance Deferred Tax Asset Change In Amount Income Tax Provision
ValuationAllowanceDeferredTaxAssetChangeInAmountIncomeTaxProvision
8977000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19584000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
127944000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9307000
CY2022 knsa Valuation Allowance Deferred Tax Asset Change In Amount Income Tax Provision
ValuationAllowanceDeferredTaxAssetChangeInAmountIncomeTaxProvision
-108360000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1794000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
545000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
545000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
837000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
528000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1386000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
50000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
411000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
137000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
342000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
102000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1794000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
545000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
837000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
183363000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-157924000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-161381000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69382275
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68576810
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61842722
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70421322
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68576810
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61842722
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.64
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.30
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.61
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.60
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.30
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.61
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9951421
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10111867
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10164170
CY2022Q4 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
22851000
CY2022Q4 knsa Purchase Commitment Obligation Due In Next Rolling Twelve Months
PurchaseCommitmentObligationDueInNextRollingTwelveMonths
22851000
CY2022 knsa Defined Contribution Plan Employer Matching Contribution Percent Of Match First Three Percent
DefinedContributionPlanEmployerMatchingContributionPercentOfMatchFirstThreePercent
1
CY2022 knsa Defined Contribution Plan Employer Matching One Hundred Percent Contribution Percent Of Employees Gross Pay
DefinedContributionPlanEmployerMatchingOneHundredPercentContributionPercentOfEmployeesGrossPay
0.03
CY2022 knsa Defined Contribution Plan Employer Matching Contribution Percent Of Match Next Two Percent
DefinedContributionPlanEmployerMatchingContributionPercentOfMatchNextTwoPercent
0.50
CY2022 knsa Defined Contribution Plan Employer Matching Fifty Percent Contribution Percent Of Employees Gross Pay
DefinedContributionPlanEmployerMatchingFiftyPercentContributionPercentOfEmployeesGrossPay
0.02
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1683000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1558000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
993000

Files In Submission

Name View Source Status
knsa-20221231_cal.xml Edgar Link unprocessable
0001558370-23-002684-index-headers.html Edgar Link pending
0001558370-23-002684-index.html Edgar Link pending
0001558370-23-002684.txt Edgar Link pending
0001558370-23-002684-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
knsa-20221231.xsd Edgar Link pending
knsa-20221231x10k.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
knsa-20221231x10k006.jpg Edgar Link pending
knsa-20221231x10k008.jpg Edgar Link pending
knsa-20221231xex23d1.htm Edgar Link pending
knsa-20221231xex31d1.htm Edgar Link pending
knsa-20221231xex31d2.htm Edgar Link pending
knsa-20221231xex32d1.htm Edgar Link pending
knsa-20221231xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
knsa-20221231_def.xml Edgar Link unprocessable
knsa-20221231_lab.xml Edgar Link unprocessable
knsa-20221231_pre.xml Edgar Link unprocessable
knsa-20221231x10k_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending